RE: 10p this year fair target16 Jan 2025 20:55
VAL is looking to out-license both VAL201 and VAL401 to TheoremRx and Ambrose Healthcare, respectively. VAL’s letter of intent with TheoremRx has just been extended to 31 May 2025 while Review- TheoremRx undertakes its own transaction with a NASDAQ-listed entity. In November, Ambrose exercised a six-month extension option to give it more time to evaluate VAL401. The new CEO clearly believes in the company, as evidenced by the 6.0% holding of the enlarged share capital taken in the recent £1.57m fundraise at 0.65p per share.